OBJECTIVE: Familial combined hyperlipidemia (FCHL) is associated with variable lipid and lipoprotein phenotypes arbitrarily defined as type IIa, IIb, and IV based on plasma total cholesterol and triglyceride levels. This study sought to characterize consistent lipoprotein and lipid abnormalities across the 3 lipoprotein phenotypes in 62 patients with documented FCHL (IIa [n=14], IIb [n=19], and IV [n=29]) and 44 healthy individuals. METHODS AND RESULTS: The lipoprotein cholesterol distribution was determined over 38 fractions obtained by density gradient ultracentrifugation. As expected, FCHL patients with hypertriglyceridemia (IIb and IV) had higher cholesterol levels in VLDL than IIa, whereas IIa showed higher cholesterol in the big, buoyant LDL and in HDL. LDL cholesterol was higher in IIb than IV; most of the increase in LDL cholesterol was associated with big, buoyant LDL rather than small, dense LDL (sdLDL). The differences in lipoproteins between phenotypes were attributable to changes in VLDL and big, buoyant LDL levels. Comparison of the FCHL patients with healthy individuals showed a significant elevation in plasma apolipoprotein B levels and sdLDL in all 3 FCHL phenotypes. CONCLUSIONS: Although triglyceride and cholesterol levels are variable by lipoprotein phenotype, sdLDL and elevated plasma apolipoprotein B levels are consistent characteristics of FCHL shared by the 3 different lipoprotein phenotypes.
OBJECTIVE: Familial combined hyperlipidemia (FCHL) is associated with variable lipid and lipoprotein phenotypes arbitrarily defined as type IIa, IIb, and IV based on plasma total cholesterol and triglyceride levels. This study sought to characterize consistent lipoprotein and lipid abnormalities across the 3 lipoprotein phenotypes in 62 patients with documented FCHL (IIa [n=14], IIb [n=19], and IV [n=29]) and 44 healthy individuals. METHODS AND RESULTS: The lipoprotein cholesterol distribution was determined over 38 fractions obtained by density gradient ultracentrifugation. As expected, FCHL patients with hypertriglyceridemia (IIb and IV) had higher cholesterol levels in VLDL than IIa, whereas IIa showed higher cholesterol in the big, buoyant LDL and in HDL. LDL cholesterol was higher in IIb than IV; most of the increase in LDL cholesterol was associated with big, buoyant LDL rather than small, dense LDL (sdLDL). The differences in lipoproteins between phenotypes were attributable to changes in VLDL and big, buoyant LDL levels. Comparison of the FCHL patients with healthy individuals showed a significant elevation in plasma apolipoprotein B levels and sdLDL in all 3 FCHL phenotypes. CONCLUSIONS: Although triglyceride and cholesterol levels are variable by lipoprotein phenotype, sdLDL and elevated plasma apolipoprotein B levels are consistent characteristics of FCHL shared by the 3 different lipoprotein phenotypes.
Authors: Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef Journal: Nat Rev Endocrinol Date: 2012-02-14 Impact factor: 43.330
Authors: Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Anton Stalenhoef Journal: Best Pract Res Clin Endocrinol Metab Date: 2013-10-17 Impact factor: 4.690
Authors: Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik Journal: Hum Genet Date: 2010-04-11 Impact factor: 4.132
Authors: Roberto Ferrari; Carlos Aguiar; Eduardo Alegria; Riccardo C Bonadonna; Francesco Cosentino; Moses Elisaf; Michel Farnier; Jean Ferrières; Pasquale Perrone Filardi; Nicolae Hancu; Meral Kayikcioglu; Alberto Mello E Silva; Jesus Millan; Željko Reiner; Lale Tokgozoglu; Paul Valensi; Margus Viigimaa; Michal Vrablik; Alberto Zambon; José Luis Zamorano; Alberico L Catapano Journal: Eur Heart J Suppl Date: 2016-04-12 Impact factor: 1.803
Authors: Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef Journal: Arterioscler Thromb Vasc Biol Date: 2009-10-15 Impact factor: 8.311
Authors: Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef Journal: J Clin Endocrinol Metab Date: 2012-09 Impact factor: 5.958
Authors: Antonio López-Ruiz; María M Jarabo; María L Martínez-Triguero; Maria Morales-Suárez-Varela; Eva Solá; Celia Bañuls; Marta Casado; Antonio Hernández-Mijares Journal: Lipids Health Dis Date: 2009-03-31 Impact factor: 3.876
Authors: Adriana Huertas-Vazquez; Christopher L Plaisier; Ruishuang Geng; Blake E Haas; Jenny Lee; Marleen M Greevenbroek; Carla van der Kallen; Tjerk W A de Bruin; Marja-Riitta Taskinen; Kumar N Alagramam; Päivi Pajukanta Journal: Hum Genet Date: 2009-10-09 Impact factor: 4.132